Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2017 / Cilt: 26 - Sayı: 3

Experience with Treatment of Retroperitoneal Fibrosis: Collaboration of Urology and Nephrology Departments for 26 years in Marmara University

Retroperitoneal Fibrozis Tedavisi Deneyimi: Marmara Üniversitesi Üroloji ve Nefroloji Bölümlerinin 26 Yıllık Deneyimi

Pages
305–310
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment should be specific for each patient in a multidisciplinary fashion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Retroperitoneal fibrosis (RPF) is a rare condition characterized by the presence ofinflammation and fibrosis in the retroperitoneum.
📊
Key Findings & Data:This study describes our multidisciplinary approachand our results.MATERIAL and METHODS: Patients diagnosed with RPF at Marmara University between January1990 and May 2007 were evaluated.
💡
Conclusion & Impact:Treatment should be specific for each patient in a multidisciplinary fashion.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Retroperitoneal fibrosis (RPF) is a rare condition characterized by the presence ofinflammation and fibrosis in the retroperitoneum. This study describes our multidisciplinary approachand our results.MATERIAL and METHODS: Patients diagnosed with RPF at Marmara University between January1990 and May 2007 were evaluated. Etiologies, demographic characteristics, renal functions, treatmentsand prognoses of each patient were recorded and data were analyzed.RESULTS: Of all patients, five were female, 15 were male and the mean follow-up was 11.3 years (1- 18 years). Six patients were operated unilaterally and five were operated bilaterally with ureterolysis.Median creatinine values at diagnosis were 2.75 mg/dl (0.7-6.9 mg/dl) in females, 3.2 mg/dl (0.84- 7.2mg/dl) in males and 3.11 mg/dl (0.7 - 7.2 mg/dl) in the whole group. Median baseline creatinine levelafter surgery (n=11) was found to decrease from 3.63 mg/dl (1.4-7.2 mg/dl) to 1.46 mg/dl (0.8-2.6mg/dl). Baseline and drop in creatinine were compared among patients treated with either surgical orpharmacological methods, and no statistical significance was found.CONCLUSION: Retroperitoneal fibrosis can be treated surgically and pharmacologically. Ourstudy has shown similar success for both methods. Treatment should be specific for each patient in a multidisciplinary fashion.

Özet

ÖzAMAÇ: Retroperitoneal fibrozis (RPF) retroperitoneal dokularda inflamasyon ve fibroz gelişimi ilekarakterize nadir bir durumdur. Çalışma, kliniğimizin izlediği multidispliner yaklaşımı ve sonuçlarınıdeğerlendirmektedir.GEREÇ ve YÖNTEMLER: Marmara Üniversitesi'nde Ocak 1990 ile Mayıs 2007 tarihleri arasındaRPF tanısı konulan hastaların dosyaları değerlendirildi ve her hastanın etiyolojisi, demografiközellikleri, böbrek fonksiyonları, tedavileri ve prognozları kaydedildi. Elde edilen veriler uygunistatistiksel yöntemlerle analiz edildi.BULGULAR: Hastaların beşi kadın, 15'i erkek; ortalama takip süresi 11,3 yıldı (1-18 yıl). Yirmihastanın altısına unilateral, beşine bilateral, toplam 11 (%55) hastaya üreterolizis uygulandı. Tanıanındaki ortanca kreatinin değerleri kadınlarda 2,75 mg/dl (0,7 - 6,9 mg/dl); erkeklerde 3,2 mg/dl (0,84- 7,2 mg/dl), tüm grupta ortanca 3,11 mg/dl (0,7 - 7,2 mg/dl) olarak saptandı. Cerrahi (n=11) sonrasıortanca bazal kreatinin değeri 3,63 mg/dl'den (1,4-7,2 mg/dl) 1,46 mg/dl'ye (0,8 - 2,6 mg/dl) geriledi.Cerrahi uygulanan ve uygulanmayan hastaların bazal kreatinin değerleri ve düşüşleri kıyaslandığındaistatistiksel fark ortaya konulamamıştır.SONUÇ: Retroperitoneal fibrosis nedeniyle uygulanan tedavi seçenekleri cerrahi ve farmakolojiktedaviler olmak üzere ikiye ayrılır. Çalışmamız, hastaların her iki tedavi yönteminden de benzerşekilde fayda gördüklerini göstermektedir. Tedavi seçimi her hastaya özel olmalıdır ve multidisipliner düzenlenmelidir.

🔖

Cite This Article

KOÇ, M., TANIDIR, Y., AKBAL, C., ŞİMŞEK, F., ÖZGEN, M. B., ŞEKERCİ, Ç. A. (2022). Experience with Treatment of Retroperitoneal Fibrosis: Collaboration of Urology and Nephrology Departments for 26 years in Marmara University. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 26 - Sayı: 3, 305–310. https://ajindex.com/articles/654990

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Albarran J: Retention renal per petriureterite: Liberation externa de l'uretere. Ass Fr Urol 1905;9:511-515 2. Ormond J: Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948;59(6):1072-1079 3. Alan C, Özkara H, Önder AU, Kural AR, Talat Z, Hattat H: Retroperitoneal fibrozis: Cerrahi ve medikal tedavi sonuçları. Türk Üroloji Dergisi 2004;30:106-113 4. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsärinne K, Saha H, Uitti J, Roto P: Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004;363:1422-1426 5. Miller OF, Smith LJ, Ferrara EX, McAleer IM, Kaplan GW: Presentation of idiopathic retroperitoneal fibrosis in the pediatric population. J Pediatr Surg 2003;38:1685-1688 6. Liang B, Yin Z, Guo Q, Wei Y, Liu L, Yang J: Diagnosis and treatment of retroperitoneal fibrosis: A case report. Exp Ther Med 2013;5:1236-1238 7. Ezimora A, Faulkner ML, Adebiyi O, Ogungbemile A, Marianna S-V, Nzerue C: Retroperitoneal fibrosis: A rare cause of acute renal failure. Case Rep Nephrol 2012;2012:645407 8. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C: Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant 2006;21:2485-2490 9. Kottra JJ, Dunnick NR: Retroperitoneal fibrosis. Radiol Clin North Am 1996;34:1259-1275 10. Vaglio A, Salvarani C, Buzio C: Retroperitoneal fibrosis. Lancet 2006;367:241-251 11. van Bommel EF: Retroperitoneal fibrosis. Neth J Med 2002;60:231- 242 12. Nitz GL, Hewitt CB, Straffon RA, Kiser WS, Stewart BH: Retroperitoneal malignancy masquerading as benign retroperitoneal fibrosis. J Urol 1970;103:46-49 13. Rana SS, Sharma V, Chhabra P, Sharma R, Gupta R, Mittal BR, Bhasin DK: Retroperitoneal fibrosis with a complex cystic lesion mimicking an inferior vena cava tumor. Endoscopy 2015;47:E26-E27 14. Daskalakis K, Karakatsanis A, Stålberg P, Norlén O, Hellman P: Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg 2017;104:69-75 15. Pierre S, Cordy P, Razvi H: Retroperitoneal fibrosis: A case report of spontaneous resolution. Clin Nephrol 2002;57:314-319 16. Esprit DH, Koratala A, Chornyy V, Wingo C: Obstructive nephropathy without hydronephrosis: Suspicion is the key. Urology 2017;101:e9-e10 17. Parums D, Dunn D, Dixon A, Mitchinson M: Characterization of inflammatory cells in a patient with chronic periaortitis. Am J Cardiovasc Pathol 1990;3:121-129 18.